Medicare Partially Covers Genetic Prostate Cancer Test

Medicare Partially Covers Genetic Prostate Cancer Test
shutterstock_210028999Medicare is starting to cover genetic prostate cancer tests and is considering the possibility to expand the coverage to a national level. The U.S. national health care program is going to provide diagnostic examination to assess the risk of developing prostate cancer in men, and is also planning on consulting healthcare stakeholders, in order to evaluate the viability of offering it nationwide, as announced by a Medicare administrative contractor. Even though the disease is the second most common type of cancer diagnosed in American men, causing the death of approximately 28,000 people, according to the Centers for Disease Control and Prevention, Medicare does not cover genetic prostate cancer tests, which are key in assessing a patient's probability of suffering from the disease. Even now, when it has decided to partially cover Prolaris, an exam developed by the publicly traded biotechnology company Myriad Genetics, there are several conditions. In order to receive the Prolaris test, patients must meet a series of criteria, including being considered low risk or very low risk, having a life expectancy of at least ten years and having the test ordered by a certified clinician from Myriad's database, according to the local coverage determination proposed by the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *